PHARMACOGENOMICS OPEN A NEW GATE WAY IN THE TREATMENT OF CELIAC DISEASE

Background: An immune mediated enteropathy celiac disease (CD) is an auto immune deficiency disease that is occurs due to damage to the lining of the small intestine when foods with gluten are eaten. Celiac disease is characterized by musculoskeletal digestive problems, a severe skin rash called dermatitis, herpetiformis, iron deficiency anemia (low blood count), growth problems and failure to thrive (in children), Seizures, Aphthous ulcers, tingling sensation in the legs.

Objective: Our goal is to emphasize on the treatment confusion due to misjudgment with celiac disease and irritable bowel syndrome and its treatment that become possible not only by the use of gluten free diet but can also be treated by emerging field of pharmacogenomics technology.

Methodology: In current study, a survey has been conducted with general physicians (n= 100) regarding their knowledge about misjudgment between CD and IBS. Moreover communication with Pakistan celiac society and with Abbasi Shaheed Hospital gastroenteritis specialists (who are working on this disease for past year) has been done. We analysis the general and behavioral or central nervous system conditions as well.

Results: The result shows that CD is misdiagnosed with IBS. 42% consider it a small intestine disease while 58 % thinks it’s a large intestine disorder. 73% say diagnosis can be done via anti transglutunabase anti body, 88% says TGG, igA can be helpful in detecting Celiac disorder, 48% favors endoscopy while biopsy is recommended by 52%. The outcome of this innovative research is that celiac disease that occurs genetically influence in people that can be defecate by the vaccination and people enjoy their life without any restriction.

Conclusion: The prevalence study is enormous research for celiac disease. There is no study yet on national or provincial scale that reflects any data about the number of patients existing in Pakistan. The pharmacogenomics advancement opens a new hope for the celiac disease patients, therapeutic vaccines that contain three proprietary peptides that elicit an immune response in patients with celiac disease who carry the immune recognition gene HLA-DQ2. Due to lack of awareness and varying symptoms of celiac disease make it hard to diagnose and creating a problem in timely diagnosis and management.